MTOR and neoplasm: The selective downmodulation of β catenin, by AZD6244-BEZ235 compared to PLX4720-BEZ235, suggests that dual blockade of the MAPK and PI3K/mTOR pathways could suppress a recently discovered mechanism that melanoma cells exploit to suppress development of T cell mediated anti-tumor response [29] and provides a further rationale for the association of target therapy, based on dual pathway inhibition, with immune checkpoint blockade, an approach that has greatly improved the management of advanced disease [39].